Abstract
Mycobacteria leprae(leprosy) and HIV coinfection are rare in Kenya. This is likely related to the low prevalence (1 per 10,000 of population) of leprosy. Because leprosy is no longer a public health challenge there is generally a low index of suspicion amongst clinicians for its diagnosis. Management of a HIV-1-leprosy-coinfected individual in a resource-constrained setting is challenging. Some of these challenges include difficulties in establishing a diagnosis of leprosy; the high pill burden of cotreatment with both antileprosy and antiretroviral drugs (ARVs); medications' side effects; drug interactions; scarcity of drug choices for both diseases. This challenge is more profound when managing a patient who requires second-line antiretroviral therapy (ART). We present an adult male patient coinfected with HIV and leprosy, who failed first-line antiretroviral therapy (ART) and required second-line treatment. Due to limited choices in antileprosy drugs available, the patient received monthly rifampicin and daily lopinavir-/ritonavir-based antileprosy and ART regimens, respectively. Six months into his cotreatment, he seemed to have adequate virological control. This case report highlights the challenges of managing such a patient.
Original language | English (US) |
---|---|
Article number | 698513 |
Journal | Case Reports in Medicine |
Volume | 2012 |
DOIs | |
State | Published - 2012 |
Fingerprint
ASJC Scopus subject areas
- Medicine(all)
Cite this
Human immunodeficiency virus and leprosy coinfection : Challenges in resource-limited setups. / Kwobah, Charles M.; Wools-Kaloustian, Kara; Gitau, Jane N.; Siika, Abraham M.
In: Case Reports in Medicine, Vol. 2012, 698513, 2012.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Human immunodeficiency virus and leprosy coinfection
T2 - Challenges in resource-limited setups
AU - Kwobah, Charles M.
AU - Wools-Kaloustian, Kara
AU - Gitau, Jane N.
AU - Siika, Abraham M.
PY - 2012
Y1 - 2012
N2 - Mycobacteria leprae(leprosy) and HIV coinfection are rare in Kenya. This is likely related to the low prevalence (1 per 10,000 of population) of leprosy. Because leprosy is no longer a public health challenge there is generally a low index of suspicion amongst clinicians for its diagnosis. Management of a HIV-1-leprosy-coinfected individual in a resource-constrained setting is challenging. Some of these challenges include difficulties in establishing a diagnosis of leprosy; the high pill burden of cotreatment with both antileprosy and antiretroviral drugs (ARVs); medications' side effects; drug interactions; scarcity of drug choices for both diseases. This challenge is more profound when managing a patient who requires second-line antiretroviral therapy (ART). We present an adult male patient coinfected with HIV and leprosy, who failed first-line antiretroviral therapy (ART) and required second-line treatment. Due to limited choices in antileprosy drugs available, the patient received monthly rifampicin and daily lopinavir-/ritonavir-based antileprosy and ART regimens, respectively. Six months into his cotreatment, he seemed to have adequate virological control. This case report highlights the challenges of managing such a patient.
AB - Mycobacteria leprae(leprosy) and HIV coinfection are rare in Kenya. This is likely related to the low prevalence (1 per 10,000 of population) of leprosy. Because leprosy is no longer a public health challenge there is generally a low index of suspicion amongst clinicians for its diagnosis. Management of a HIV-1-leprosy-coinfected individual in a resource-constrained setting is challenging. Some of these challenges include difficulties in establishing a diagnosis of leprosy; the high pill burden of cotreatment with both antileprosy and antiretroviral drugs (ARVs); medications' side effects; drug interactions; scarcity of drug choices for both diseases. This challenge is more profound when managing a patient who requires second-line antiretroviral therapy (ART). We present an adult male patient coinfected with HIV and leprosy, who failed first-line antiretroviral therapy (ART) and required second-line treatment. Due to limited choices in antileprosy drugs available, the patient received monthly rifampicin and daily lopinavir-/ritonavir-based antileprosy and ART regimens, respectively. Six months into his cotreatment, he seemed to have adequate virological control. This case report highlights the challenges of managing such a patient.
UR - http://www.scopus.com/inward/record.url?scp=84924869409&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84924869409&partnerID=8YFLogxK
U2 - 10.1155/2012/698513
DO - 10.1155/2012/698513
M3 - Article
AN - SCOPUS:84924869409
VL - 2012
JO - Case Reports in Medicine
JF - Case Reports in Medicine
SN - 1687-9627
M1 - 698513
ER -